HC Wainwright Reaffirms Buy Rating for Regulus Therapeutics (NASDAQ:RGLS)

Regulus Therapeutics (NASDAQ:RGLS)‘s stock had its “buy” rating reissued by HC Wainwright in a report released on Wednesday,Benzinga reports. They currently have a $10.00 target price on the biopharmaceutical company’s stock.

Regulus Therapeutics Price Performance

Regulus Therapeutics stock opened at $1.28 on Wednesday. The firm has a 50-day moving average of $1.33 and a 200-day moving average of $1.48. Regulus Therapeutics has a one year low of $0.83 and a one year high of $3.79. The company has a market cap of $83.84 million, a price-to-earnings ratio of -1.20 and a beta of 1.58.

Insider Activity at Regulus Therapeutics

In related news, CEO Joseph P. Hagan sold 115,290 shares of the firm’s stock in a transaction dated Monday, January 13th. The shares were sold at an average price of $1.26, for a total value of $145,265.40. Following the completion of the sale, the chief executive officer now directly owns 222,572 shares in the company, valued at approximately $280,440.72. This trade represents a 34.12 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, VP Christopher Ray Aker sold 38,547 shares of the firm’s stock in a transaction dated Monday, January 13th. The shares were sold at an average price of $1.26, for a total transaction of $48,569.22. Following the completion of the sale, the vice president now owns 54,634 shares of the company’s stock, valued at $68,838.84. This trade represents a 41.37 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 223,998 shares of company stock worth $282,237. Insiders own 4.35% of the company’s stock.

Institutional Investors Weigh In On Regulus Therapeutics

Several hedge funds have recently bought and sold shares of RGLS. SG Americas Securities LLC acquired a new stake in Regulus Therapeutics during the third quarter worth approximately $33,000. Creative Planning bought a new position in Regulus Therapeutics in the third quarter valued at approximately $26,000. Tyche Wealth Partners LLC increased its stake in Regulus Therapeutics by 920.6% in the third quarter. Tyche Wealth Partners LLC now owns 106,089 shares of the biopharmaceutical company’s stock valued at $167,000 after acquiring an additional 95,694 shares during the last quarter. Victory Capital Management Inc. grew its stake in shares of Regulus Therapeutics by 10.4% during the third quarter. Victory Capital Management Inc. now owns 398,866 shares of the biopharmaceutical company’s stock worth $626,000 after buying an additional 37,480 shares during the last quarter. Finally, The Manufacturers Life Insurance Company bought a new stake in shares of Regulus Therapeutics during the third quarter worth $204,000. 92.38% of the stock is currently owned by institutional investors and hedge funds.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.